Research for Photo-gamma EEG modulation to develop the therapeutics for Alzheimer’s Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0010618

Enrollment

Registered

2025-06-11

Start date

2023-02-02

Completion date

Unknown

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : -The subject executes the optical stimulation program application installed on the tablet-pc, wears the glasses-type optical stimulation device, and performs the optical stimulation program.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults 50 years of age or older who were diagnosed with mild cognitive impairment and mild Alzheimer-type dementia due to Alzheimer's disease, and those who voluntarily agreed to this study after hearing the explanation.

Exclusion criteria

Exclusion criteria: Delirium, confusion, other disorders of consciousness, major depression, major mental disorders including alcohol use disorder, past history of convulsive disorders, major central nervous system disorders, serious physical diseases such as chronic renal failure and severe cardiovascular disease, lesions other than Alzheimer's disease on brain magnetic resonance imaging , patients with severe hearing impairment, visual impairment, or speech impairment that makes it difficult to perform appropriate tests

Design outcomes

Secondary

Measure	Time frame
Neuropsychiatric and Functional Assessment: Geriatric Depression Scale-Korean version (GDS-KR), Quality of Life-Alzheimer’s disease (QOL-AD), Disability Assessment for Dementia-Korean version (DAD-K), Clinical Dementia Rating scale (CDR);Neurophysiological Assessment: Amyloid Positron Emission Tomography (A-PET) Standardized Uptake Value Ratio (SUVR) (whole brain, frontal lobe, temporal lobe, parietal lobe, anterior cingulate, posterior cingulate, precuneus), Magnetic Resonance Imaging (MRI) Whole Brain and Hippocampal Volume;Cognitive Assessment: Alzheimer's Disease Assessment Scale-Korean version cognitive subscale (ADAS-Kcog), Mini-Mental State Examination for Dementia Screening (MMSE-DS), Subjective Memory Complaint Questionnaire (SMCQ)	—

Measure

Time frame

Neuropsychiatric and Functional Assessment: Geriatric Depression Scale-Korean version (GDS-KR), Quality of Life-Alzheimer’s disease (QOL-AD), Disability Assessment for Dementia-Korean version (DAD-K), Clinical Dementia Rating scale (CDR);Neurophysiological Assessment: Amyloid Positron Emission Tomography (A-PET) Standardized Uptake Value Ratio (SUVR) (whole brain, frontal lobe, temporal lobe, parietal lobe, anterior cingulate, posterior cingulate, precuneus), Magnetic Resonance Imaging (MRI) Whole Brain and Hippocampal Volume;Cognitive Assessment: Alzheimer's Disease Assessment Scale-Korean version cognitive subscale (ADAS-Kcog), Mini-Mental State Examination for Dementia Screening (MMSE-DS), Subjective Memory Complaint Questionnaire (SMCQ)

—

Primary

Measure	Time frame
Adherence to light stimulation program and subjective discomfort, Quantitative Electroencephalogram, Event-Related Spectral Perturbation	—

Countries

Korea, Republic of

Contacts

Public ContactYeseung Park

Seoul National University Bundang Hospital

hannah3425@naver.com+82-2-787-7440

Outcome results